Tweeter button Delicious button Digg button Stumbleupon button
Liver Diseases | Fuzheng Huayu Composition May Lead To Anti-Liver Fibrosis Treatment In U.S.

SAN FRANCISCO–( BUSINESS WIRE )–At the annual Liver Meeting of American Association for Study of Liver Diseases on Nov. 6, 2011, Professor Chenghai Liu, director of the Institute of Liver Diseases at Shanghai University of Traditional Chinese Medicine, revealed the botanical preparation Fuzheng Huayu (FZHY) and the newly identified compounds may help reverse liver fibrosis in hepatitis patients.

“FZHY has been used by hundreds of thousands of patients in China and has an established track record of safety and efficacy. It will help patients with hepatitis in the U.S. and around the world if FZHY composition continues its development as an anti-fibrotic compound through clinical trials.”

Liu and his research team made the conclusion after investigating FZHY’s anti-fibrotic mechanism and active components in a liver fibrosis animal model. The examination showed FZHY inhibited liver fibrosis and reduced angiogenesis in liver-fibrotic mice.

After screening 21 components from the plant-based drug, using microvessel density and liver sinusoidal structural changes, Liu and his team identified several new compounds.

Liu stressed liver fibrosis reduction is critical in treating chronic liver diseases because liver cell damages such as inflammation normally stimulate several risk factors, including activation of hepatic stellate cells.

“The hepatic stellate cells are under a ‘sleep’ mode in normal conditions,” he explained. “However, when stimulated by inflammatory factors, the hepatic stellate cells ‘awaken,’ secreting large amounts of collagen. The aggregated collagen forms dense and tough fibrous connective tissues, which is fibrosis.”

Manufactured by Shanghai Sundise Traditional Chinese Medicine, Co., Ltd. (Sundise), FZHY is an approved anti-fibrotic drug for treating hepatitis B infection in China and Hong Kong. In a newly published, 16-hospital study (sponsored by Sundise) with 590 hepatitis B patients in China, FZHY’s efficacy against liver fibrosis was 52-58.3 percent after the drug was administered for six months.

Other clinical trials conducted in China show FZHY improves hepatic inflammation, regulates fat metabolism, reduces

Click here to view rest of article from original site

Native Remedies Liver Doctor And Detox Drops Combopack  by Native Native Remedies Liver Doctor And Detox Drops Combopack  by Native
2 new from $40.28
Live Disease Free To 103  by Jim Shriner Live Disease Free To 103  by Jim Shriner

4 new from $29.98

Facebook Twitter Email

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.